NASDAQ · TGTX
TG Therapeutics, Inc.
$58.08+$0.68 (+1.18%)
TG Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 2.06% below the high.
Loading market information…
NASDAQ · IMVT · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Immunovant, Inc.’s quoted price sits in the lower half of its reported 52-week range, 34.74% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Immunovant, Inc.’s next earnings report is currently expected on Nov 9, 2026, with estimated earnings per share of -$0.74. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Immunovant, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advancing novel monoclonal antibody therapies for the treatment of various autoimmune conditions. The company's primary focus is batoclimab, a pioneering, fully human monoclonal antibody. This antibody is engineered to specifically target and block the neonatal fragment crystallizable receptor (FcRn), a key mechanism in certain autoimmune diseases. Batoclimab is currently undergoing Phase IIa clinical evaluations for treating both myasthenia gravis and thyroid eye disease. Additionally, it has commenced Phase II clinical studies for patients suffering from warm autoimmune hemolytic anemia. Established in 2018, Immunovant operates from its headquarters in New York, New York, functioning as a subsidiary under the umbrella of Roivant Sciences Ltd.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:09 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| $0.00 |
| Q3 2025 | Feb 6, 2025 | -$0.76-4.11% vs estimate | $0.00 |
|---|
| Q2 2025 | Nov 7, 2024 | -$0.74-21.31% vs estimate | $0.00 |
|---|
THE ANALYST VIEW
23 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 1 contributors · Median target $40.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$58.08+$0.68 (+1.18%)
TG Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 2.06% below the high.
$28.76-$0.01 (-0.03%)
Zenas BioPharma, Inc.’s quoted price sits in the lower half of its reported 52-week range, 35.52% below the high.
$45.23-$0.50 (-1.08%)
First Tracks Biotherapeutics Inc’s quoted price sits in the upper half of its reported 52-week range, 9.39% below the high.
$48.64-$1.86 (-3.68%)
AnaptysBio, Inc.’s quoted price sits in the upper half of its reported 52-week range, 32.78% below the high.
$15.45-$0.11 (-0.71%)
Cullinan Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 33.38% below the high.
$4.01-$0.03 (-0.74%)
Annexon, Inc.’s quoted price sits in the lower half of its reported 52-week range, 44.15% below the high.
$3.99+$0.03 (+0.76%)
Aclaris Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 39.55% below the high.
$1.59+$0.07 (+4.28%)
Cabaletta Bio, Inc.’s quoted price sits in the lower half of its reported 52-week range, 62.53% below the high.
